Univariate analysis of outcomes (cumulative incidences—95% confidence interval) after unrelated bone marrow (UBMT), T-cell–depleted unrelated bone marrow (T-UBMT), and unrelated cord blood transplants (UCBT) nonadjusted for differences in prognostic factors
| Outcomes . | UBMT (n = 262) . | T-UBMT (n = 180) . | UCBT (n = 99) . |
|---|---|---|---|
| Neutrophil recovery at day 60 | 96% (95-97) | 90% (84-96) | 80% (70-90) |
| Median days (95Cl) | 18 (10-40) | 16 (9-40) | 32 (11-56) |
| Recoveries (n) | 243 | 151 | 70 |
| Platelet recovery at day 180 | 85% (79-91) | 85% (77-93) | 90% (80-100) |
| Median days (95Cl) | 29 (8-141) | 29 (8-165) | 81 (16-159) |
| Recoveries (n) | 201 | 129 | 49 |
| Early TRM at day 100 | 19% (14-24) | 14% (9-20) | 39% (29-48) |
| Nonleukemic deaths (n) | 49 | 25 | 38 |
| Acute GVHD (II-IV) at day 100 | 58% (51-63) | 20% (15-25) | 35% (24-45) |
| Grade 0 (n, %) | 51 (20%) | 97 (54%) | 43 (43%) |
| Grade I | 63 (24%) | 49 (27%) | 23 (23%) |
| Grade II | 71 (27%) | 20 (11%) | 12 (12%) |
| Grade III | 55 (21%) | 10 (6%) | 11 (11%) |
| Grade IV | 22 (8%) | 4 (2%) | 10 (10%) |
| Acute GVHD (II-IV) (n) | 148 | 34 | 33 |
| Acute GVHD (III-IV) | 30% (24-36) | 8% (0-16) | 22% (14-30) |
| Acute GVHD (n) | 77 | 14 | 21 |
| Chronic GVHD at 2 years | 46% (37-53) | 12% (6-17) | 25% (1-17) |
| Chronic GVHD (n/patients at risk5-150) | 86/201 (43%) | 14/124 (11%) | 5/43 (12%) |
| Relapse at 2 years | 39% (32-46) | 47% (39-55) | 38% (25-53) |
| relapses (n) | 75 | 66 | 23 |
| Survival at 2 years | 49% (43-55) | 41% (33-49) | 35% (25-45) |
| Deaths (n) | 133 | 104 | 63 |
| EFS at 2 years | 43% (37-49) | 37% (30-44) | 31% (21-41) |
| Deaths and or relapses (n) | 146 | 110 | 67 |
| Outcomes . | UBMT (n = 262) . | T-UBMT (n = 180) . | UCBT (n = 99) . |
|---|---|---|---|
| Neutrophil recovery at day 60 | 96% (95-97) | 90% (84-96) | 80% (70-90) |
| Median days (95Cl) | 18 (10-40) | 16 (9-40) | 32 (11-56) |
| Recoveries (n) | 243 | 151 | 70 |
| Platelet recovery at day 180 | 85% (79-91) | 85% (77-93) | 90% (80-100) |
| Median days (95Cl) | 29 (8-141) | 29 (8-165) | 81 (16-159) |
| Recoveries (n) | 201 | 129 | 49 |
| Early TRM at day 100 | 19% (14-24) | 14% (9-20) | 39% (29-48) |
| Nonleukemic deaths (n) | 49 | 25 | 38 |
| Acute GVHD (II-IV) at day 100 | 58% (51-63) | 20% (15-25) | 35% (24-45) |
| Grade 0 (n, %) | 51 (20%) | 97 (54%) | 43 (43%) |
| Grade I | 63 (24%) | 49 (27%) | 23 (23%) |
| Grade II | 71 (27%) | 20 (11%) | 12 (12%) |
| Grade III | 55 (21%) | 10 (6%) | 11 (11%) |
| Grade IV | 22 (8%) | 4 (2%) | 10 (10%) |
| Acute GVHD (II-IV) (n) | 148 | 34 | 33 |
| Acute GVHD (III-IV) | 30% (24-36) | 8% (0-16) | 22% (14-30) |
| Acute GVHD (n) | 77 | 14 | 21 |
| Chronic GVHD at 2 years | 46% (37-53) | 12% (6-17) | 25% (1-17) |
| Chronic GVHD (n/patients at risk5-150) | 86/201 (43%) | 14/124 (11%) | 5/43 (12%) |
| Relapse at 2 years | 39% (32-46) | 47% (39-55) | 38% (25-53) |
| relapses (n) | 75 | 66 | 23 |
| Survival at 2 years | 49% (43-55) | 41% (33-49) | 35% (25-45) |
| Deaths (n) | 133 | 104 | 63 |
| EFS at 2 years | 43% (37-49) | 37% (30-44) | 31% (21-41) |
| Deaths and or relapses (n) | 146 | 110 | 67 |
Patients at risk: survivors after day 100 with sustained engraftment.
GVHD indicates graft-versus-host disease; TRM, transplant-related mortality; and EFS, event-free survival.